Parnell Pharmaceuticals (OTCMKTS:PARNF) is an international animal health company headquartered in Alexandria, New South Wales, Australia. The company specializes in the development, manufacture and commercialization of veterinary pharmaceutical products designed to alleviate pain and promote healing in livestock. Its flagship product, Tri-Solfen, is a topical anesthetic and antiseptic gel used in procedures such as castration, dehorning and tail docking in sheep and cattle. Tri-Solfen’s unique formulation combines local anesthetic, antiseptic and disinfectant agents to provide immediate pain relief and protect wounds from secondary infection.
In addition to Tri-Solfen, Parnell has expanded its portfolio through strategic partnerships and licensing agreements to bring innovative therapies to the global animal health market. The company’s research and development efforts focus on improving drug delivery systems, extending product shelf life and securing regulatory approvals in key markets. Parnell holds registrations for Tri-Solfen and other products with the Australian Pesticides and Veterinary Medicines Authority (APVMA), and continues to pursue registrations in regions including New Zealand, Latin America and Southeast Asia.
Founded in the late 1990s as a specialty veterinary product manufacturer, Parnell has built a reputation for science-led innovation in pain management for farm animals. The executive team comprises professionals with extensive experience in veterinary medicine, pharmaceutical development and global commercial operations. Parnell leverages contract manufacturing partnerships in Australia and overseas to scale production while maintaining stringent quality control standards.
With a focus on animal welfare and sustainable livestock farming, Parnell Pharmaceuticals invests in ongoing clinical research and field trials to demonstrate product performance and safety. The company actively collaborates with academic institutions, veterinary associations and industry bodies to support best practice in pain management and enhance the adoption of its products. As it expands its geographic footprint and product line, Parnell aims to address unmet needs in the veterinary market and deliver value to farmers, veterinarians and shareholders alike.
AI Generated. May Contain Errors.
Free PARNF Stock Alerts